We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...
In July 2003. the company launched Lantus, the worlds first and only once a day insulin and in December 2003, Actonel, designed for the treatment of osteoporosis was launched.In the year 2004 ...
Barchart on MSN20h
Artificial Pancreas Maker Beta Bionics Just Started Trading. Should You Buy BBNX Stock After Its IPO?Beta Bionics (BBNX) leads innovation in the diabetes treatment market with its groundbreaking iLet Bionic Pancreas technology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback